Stratasys Launches Selective Absorption Fusion (SAF) 3D Printer Range for PBF Production

Stratasys Launches Selective Absorption Fusion (SAF) 3D Printer Range for PBF Production

by Technologies

Stratasys is again incrementing the company’s presence in the rapidly expanding area of production-grade 3D printing systems. After acquiring Origin for high-speed photopolymerization and RPS for large format stereolithography, the company just presented the upcoming line of powder bed fusion (PBF) based 3D printers. The new H Series Production Platform will be powered by Selective Absorption Fusion technology specifically designed to meet the needs of volume manufacturing. Commercial availability of 3D printers based on SAF technology is currently expected in the third quarter of 2021.

Ford and HP Reuse Spent 3D Printed Powders and Parts Sustainability

Ford and HP Reuse Spent 3D Printed Powders and Parts Sustainability

by Environment

Ford teamed up with HP to reuse spent 3D-printed powders and parts, thus closing a supply chain loop and turning them into injection-molded vehicle parts. The recycled materials are being used to manufacture injection-molded fuel-line clips installed first on Super Duty F-250 trucks. The parts have better chemical and moisture resistance than conventional versions, are 7% lighter and cost 10% less. The Ford research team has identified 10 other fuel-line clips on existing vehicles that could benefit from this innovative use of material and are migrating it to future models.

Renishaw 3D Printed Medical Device Breaks Ground in Parkinson’s Drug Trial

Renishaw 3D Printed Medical Device Breaks Ground in Parkinson’s Drug Trial

by Medical

Renishaw additive manufacturing has played a pivotal role in the recent clinical trial of an experimental treatment for Parkinson’s Disease. Documented in a two part-series produced by the BBC titled The Parkinson’s Drug Trial: A Miracle Cure? this trial includes the novel development of 3D printed medical device capable of delivering drugs directly to affected parts of the brain. After 40-80 weeks in-situ, the implants have become part of a potentially landmark advance in the treatment of this long-term degenerative disorder.